Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891112 | 0.83 | NPC1 (0.35) | MAPTNPC1ALDH1A1GAARAB9A | |
| SCHEMBL12107669 | 0.79 | MME (0.32) | MAPTNPC1ALDH1A1GAARAB9A | |
| SCHEMBL13802677 | 0.78 | MAPT (0.41) | MAPTNPC1ALDH1A1GAARAB9A | |
| SCHEMBL11912104 | 0.78 | MAPT (0.41) | MAPTNPC1ALDH1A1GAARAB9A | |
| SCHEMBL21153268 | 0.75 | MME (0.33) | MAPTNPC1ALDH1A1GAARAB9A | |
| SCHEMBL13178384 | 0.74 | MME (0.43) | MAPTMMEPIK3CD | |
| SCHEMBL15040816 | 0.74 | MME (0.43) | MAPTMMEPIK3CD | |
| SCHEMBL16202441 | 0.74 | MME (0.36) | MAPTMMEPIK3CD | |
| SCHEMBL2931296 | 0.74 | MME (0.43) | MAPTMMEPIK3CD | |
| SCHEMBL13544349 | 0.74 | KMT2A (0.45) | MAPTGAASMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20120276124-A1 | MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276124-A1 | MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | C1R, OGFR, ARRB1 | MAPT 3150/4885NPC1 1353/4885ALDH1A1 1524/4885 |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRP, GABRA1 | MAPT 1404/4885NPC1 2391/4885ALDH1A1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.